Shandong Sito Bio-Technology Co.Ltd(300583)
Opinions of independent directors on matters related to the seventh meeting of the third board of directors
Prior approval opinion
In accordance with the rules for independent directors of listed companies, the measures for the administration of securities issuance and registration of companies listed on the gem (for Trial Implementation), the detailed rules for the implementation of non-public development of shares by listed companies (revised in 2020), the self regulatory guidelines for companies listed on the gem of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem and other laws and regulations, normative documents and relevant provisions of the articles of association, As an independent director of Shandong Sito Bio-Technology Co.Ltd(300583) (hereinafter referred to as “the company”), based on the position of independent judgment, in line with the attitude of being responsible to the company, all shareholders and investors, and adhering to the principle of seeking truth from facts, we have reviewed in advance the proposal on ending the issuance of A-Shares to specific objects in 2021 and withdrawing the application documents considered at the seventh meeting of the third board of directors of the company. Now we express the following prior approval opinions:
The company’s decision to terminate the issue of A-Shares to specific objects in 2021 and withdraw the application documents is made after careful analysis, taking into account the changes of the current capital market environment and financing opportunities, combined with the actual situation of the company, future development planning and other factors. It is understood that the company’s current business operations are normal. The withdrawal of relevant application documents will not have a significant impact on the company’s daily production and operation, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders. Therefore, after prior deliberation, we agreed to submit the proposal to the seventh meeting of the third board of directors of the company for deliberation.
Independent director: Zhang Qiming, Tu Pengfei, Qing Beijun
April 6, 2002
